Long-term Follow-up of Cytomegalovirus Retinitis in Non-HIV Immunocompromised Patients: Clinical Features and Visual Prognosis

Am J Ophthalmol. 2016 May:165:145-53. doi: 10.1016/j.ajo.2016.03.015. Epub 2016 Mar 19.

Abstract

Purpose: To evaluate clinical features and long-term visual outcome of cytomegalovirus (CMV) retinitis in patients without human immunodeficiency virus (HIV) infection, and to determine factors that predict visual outcome.

Design: Retrospective cohort study.

Methods: Consecutive patients with CMV retinitis without HIV infection were reviewed. Main outcome measures included clinical features, proportion of eyes with 6-month and final visual acuity (VA) <20/70 and <20/400, and odds ratios of factors associated with poor visual outcome.

Results: A total of 20 eyes from 13 patients were included with a median follow-up time of 17 months. All had at least 6 months of follow-up except 1 patient who died from sepsis at 1 month. At presentation, 50% of eyes had VA <20/70 and 25% had VA <20/400. Zone 1 involvement occurred in 55% and vitreous haze ≥grade 2+ occurred in 25%. Recurrence occurred in 33.3% at a mean time of 6.4 ± 3.3 weeks after discontinuation of anti-CMV therapy. The retinal detachment rate was 21.7% per eye-year and mortality rate was 11.7% per person-year. At final visit, 60% had VA <20/70 and 35% had VA <20/400. Macular involvement was significantly associated with poor final VA <20/400 (odds ratio = 25.00, P = .016).

Conclusions: CMV retinitis without HIV infection was often aggressive at presentation. Significant intraocular inflammation was not uncommon. The long-term visual outcome was poor, especially in those with macular involvement.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antiviral Agents / therapeutic use
  • Cohort Studies
  • Cytomegalovirus Retinitis / diagnosis*
  • Cytomegalovirus Retinitis / drug therapy
  • Cytomegalovirus Retinitis / physiopathology
  • Female
  • Follow-Up Studies
  • Ganciclovir / analogs & derivatives
  • Ganciclovir / therapeutic use
  • HIV Infections / diagnosis
  • Humans
  • Immunocompromised Host*
  • Male
  • Middle Aged
  • Prognosis
  • Recurrence
  • Retinal Detachment / diagnosis
  • Retinal Detachment / physiopathology
  • Retrospective Studies
  • Valganciclovir
  • Vision Disorders / diagnosis
  • Vision Disorders / physiopathology
  • Visual Acuity / physiology*

Substances

  • Antiviral Agents
  • Valganciclovir
  • Ganciclovir